Caribou Biosciences, Inc. — Income Charts
2 years of history · ending 2025-12-31 · SEC EDGAR
Source:10-K · 10-Q
Revenue, Gross Profit, Operating Income & Net Income
Margin (%)
Operating Expenses
Income Breakdown
Revenue
$11M
R&D
$109M
D&A
$4M
Operating Income
$-148M
EBITDA
$-145M
Interest Expense
—
Other Income/Expense
$-331K
Pretax Income
$-149M
Tax Provision
$-550K
Net Income
$-148M
Operating Margin
-1329.4%
Net Margin
-1327.4%
Effective Tax Rate
0.4%
Deferred Tax Assets
$4M
Deferred Tax Liabilities
$0
DTA Valuation Allowance
$187M
ETR (Continuing Operations)
0.4%
ETR Federal Statutory
21.0%
ETR State + Local (pp)
0.5%
Operating Lease Cost
$8M
Revenue YoY Variation
11.7%
Income YoY Variation
11.0%